Cytogenetic characteristics of B cell chronic lymphocytic leukemia in 275 chinese patients by fluorescence in situ hybridization: A multicenter study

Chinese Medical Journal

Volumn 124, Issue 16, 2011, Pages 2417-2422

  Lai, Yue Yun ^a   Huang, Xiao Jun ^a  

^a PEKING UNIVERSITY   (China)

Author keywords

Chronic lymphocytic leukemia; Cytogenetics; Fluorescence; In situ hybridization

Indexed keywords

ALKYLATING AGENT; FLUDARABINE; HEMOGLOBIN; LACTATE DEHYDROGENASE;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER STAGING; CANCER SURVIVAL; CHINESE; CHROMOSOME DELETION 13; CHROMOSOME DELETION 13Q; CHROMOSOME DELETION 22Q11; CHRONIC LYMPHATIC LEUKEMIA; CYTOGENETICS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENETIC DISORDER; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROGNOSIS; THROMBOCYTE COUNT; TRISOMY 12; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CHROMOSOME ABERRATIONS; CHROMOSOME DELETION; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; TRISOMY;

EID: 80052008536     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.16.004     Document Type: Article

References (30)

1. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
2. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
3. Mayr C, Speicher MR, Kofler DM, Buhmann R, Strehl J, Busch R, et al. Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood 2006; 107: 742-751.
4. Dewald GW, Brockman SR, Paternoster SF, Bone ND, O'Fallon JR, Allmer C, et al. Chromosome anomalies detected by interphase fluorescence in situ hybridization: correlation with significant biological features of B-cell chronic lymphocytic leukaemia. Br J Haematol 2003; 121: 287-295.
5. Nelson BP, Gupta R, Dewald GW, Paternoster SF, Rosen ST, Peterson LC. Chronic lymphocytic leukemia FISH panel: impact on diagnosis. Am J Clin Pathol 2007; 128: 323-332.
6. Glassman AB, Hayes KJ. The value of fluorescence in situ hybridization in the diagnosis and prognosis of chronic lymphocytic leukemia. Cancer Genet Cytogenet 2005; 158: 88-91.
7. Kröber A, Seiler T, Benner A, Bullinger L, Brückle E, Lichter P, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002; 100: 1410-1416.
8. Oscier DG, Gardiner AC, Mould SJ, Glide S, Davis ZA, Ibbotson RE, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002; 100: 1177-1184.
9. Durak B, Akay OM, Aslan V, Ozdemir M, Sahin F, Artan S, et al. Prognostic impact of chromosome alterations detected by FISH in Turkish patients with B-cell chronic lymphocytic leukemia. Cancer Genet Cytogenet 2009; 188: 65-69.
10. Nowakowski GS, Dewald GW, Hoyer JD, Paternoster SF, Stockero KJ, Fink SR, et al. Interphase fluorescence in situ hybridization with an IGH probe is important in the evaluation of patients with a clinical diagnosis of chronic lymphocytic leukaemia. Br J Haematol 2005; 130: 36-42.
11. Qiu HX, Xu W, Cao XS, Zhou M, Shen YF, Xu YL, et al. Cytogenetic characterisation in Chinese patients with chronic lymphocytic leukemia: a prospective, multicenter study on 143 cases analysed with interphase fluorescence in situ hybridisation. Leuk Lymphoma 2008; 49: 1887-1892.
12. Xu W, Li JY, Wu YJ, Yu H, Shen QD, Li L, et al. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia. Leuk Res 2008; 32: 1071-1077.
13. Xu W, Li JY, Pan JL, Qiu HR, Shen YF, Li L, et al. Interphase fluorescence in situ hybridization detection of cytogenetic abnormalities in B-cell chronic lymphocytic leukemia. Int J Hematol 2007; 85: 430-436.
14. Irons RD, Le A, Bao LM, Zhu XZ, Ryder J, Wang XQ, et al. Characterization of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Shanghai, China: Molecular and cytogenetic characteristics, IgV gene restriction and hypermutation patterns. Leuk Res 2009; 33: 1599-1603.
15. Shaffer LG, Tommerup N. An international system for human cytogenetic nomenclature (ISCN, 2005). Basel: S. Karger Publishers; 2005.
16. Van Bockstaele F, Verhasselt B, Philippé J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 2009; 23: 25-47.
17. Put N, Konings P, Rack K, Jamar M, Van Roy N, Libouton JM, et al. Improved detection of chromosomal abnormalities in chronic lymphocytic leukemia by conventional cytogenetics using CpG oligonucleotide and interleukin-2 stimulation: a Belgian multicentric study. Genes Chromosomes Cancer 2009; 48: 843-853.
18. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2003; 103: 1202-1210.
19. Seiler T, Döhner H, Stilgenbauer S. Risk stratification in chronic lymphocytic leukemia. Semin Oncology 2006; 33: 186-194.
20. Ripollés L, Ortega M, Ortuño F, González A, Losada J, Ojanguren J, et al. Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia. Cancer Genet Cytogenet 2006; 171: 57-64.
21. Haferlach C, Dicker F, Schnittger S, Kern W, Haferlach T. Comprehensive genetic characterization of CLL: a study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia 2007; 21: 2442-2451.
22. Dicker F, Herholz H, Schnittger S. The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype. Leukemia 2009; 23: 117-124.
23. Athanasiadou A, Stamatopoulos K, Tsompanakou A, Gaitatzi M, Kalogiannidis P, Anagnostopoulos A, et al. Clinical, immunophenotypic, and molecular profiling of trisomy 12 in chronic lymphocytic leukemia and comparison with other karyotypic subgroups defined by cytogenetic analysis. Cancer Genetics Cytogenetics 2006; 168: 109-119.
24. Cuneo A, Bigoni R, Rigolin GM, Roberti MG, Bardi A, Cavazzini F, et al. Late appearance of the 11q22.3-23.1 deletion involving the ATM locus in B-cell chronic lymphocytic leukemia and related disorders: clinico-biological significance. Haematologica 2002; 87: 44-51.
25. Hjalmar V, Hast R, Kimby E. Sequential fluorescence in situ hybridization analyses for trisomy 12 in chronic leukemic B-cell disorders. Haematologica 2001; 86: 174-180.
26. Chena C, Arrossagaray G, Scolnik M, Palacios MF, Slavutsky I. Interphase cytogenetic analysis in Argentinean B-cell chronic lymphocytic leukemia patients: association of trisomy 12 and del(13q14). Cancer Genet Cytogenet 2003; 146: 154-160.
27. AbdelSalam M, El Sissy A, Samra MA, Ibrahim S, El Markaby D, Gadallah F, et al. The impact of trisomy 12, retinoblastoma gene and P53 in prognosis of B-cell chronic lymphocytic leukemia. Hematology 2008; 13: 147-153.
28. Zenz T, Döhner H, Stilgenbauer S. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007; 20: 439-453.
29. Reddy KS. Chronic lymphocytic leukaemia profiled for prognosis using a fluorescence in situ hybridisation panel. Br J Haematol 2006; 132: 705-722.
30. Sindelárová L, Michalová K, Zemanová Z, Ransdorfová S, Brezinová J, Peková S, et al. Incidence of chromosomal anomalies detected with FISH and their clinical correlations in B-chronic ly mphocytic leukemia. Cancer Genet Cytogenet 2005; 160: 27-34.